

Pfizer Inc.  
275 North Field Drive  
Lake Forest, IL 60045



February 12, 2020

**Recovery Notification for  
Vincristine Sulfate Injection, USP Presentations**

Dear Valued Customer,

We are very pleased to inform you that Pfizer's Vincristine Sulfate Injection, USP, is now fully recovered as a result of deliveries being expedited.

Recovered means that Pfizer's customers have sufficient inventory of both the 1 mg and 2 mg presentations on their shelves, wholesalers and distributors are fully stocked, and Pfizer maintains eight weeks or more of inventory in its distribution centers. The company has delivered approximately 130,000 patient doses of vincristine since January 1 of this year; which equates to more than four times historical demand.

In addition, the U.S. Food and Drug Administration has removed Pfizer's vincristine from its drug shortage list.

Now that wholesalers and distributors are fully restocked with vincristine, customers should resume ordering both the 1 mg and 2 mg presentations through them:

- Vincristine Sulfate Injection, USP 1 mg/mL, Single Dose ONCO-TAIN™ Glass Fliptop Vial, (Unit of Sale NDC: 61703-0309-06)
- Vincristine Sulfate Injection, USP 2 mg/2 mL (1 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial, (Unit of Sale NDC: 61703-0309-16)

Pfizer recognizes the importance of vincristine and we are pleased that this vital medication once again is available to providers, without any restrictions.

To review the most up-to-date information on product availability, please download the Availability Report from our PfizerHospitalUS.com website. You can also contact our Supply Continuity Team between 7:00am – 6:00pm CT, M - F, to discuss any product availability questions at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]).

Thank you,

Chris Hernandez  
Portfolio Director, Oncology and Alternate Site  
Pfizer Hospital Business Unit U.S.